See all results for “”
PEPTIDE SUPERMARKET®

Cagrilintide Price Comparison

Live prices from 9 SA suppliers, from R510.00, compared side by side so you never overpay.

GLP-1 & metabolic research Prices checked
We compare prices & may earn a commission. We do not sell or supply any products. Full disclosure.

We may earn a commission from the suppliers listed here. Read our full disclosure.

Best Price R510.00
Average R1,115.00
Highest R1,850.00
You Could Save 72%
6 results
Best Price
Save 72%
Crono Pharm logo
Crono Pharm

Cagrilintide

In Stock 10mg Lab Tested
R510.00
+ R150.00 delivery
White Rabbit Labs logo
White Rabbit Labs

Cagrilintide 10mg

R750.00
In Stock 10mg
Save 59% + R120.00 delivery
Crono Pharm logo
Crono Pharm

Cagrilintide

R900.00
In Stock 10mg Lab Tested Pen
Save 51% + R150.00 delivery
Striata Labs logo
Striata Labs

Cagrilintide 10mg

R1,080.00
In Stock 10mg Lab Tested
Save 42% + R150.00 delivery
Health & Fitness ZA logo
Health & Fitness ZA

Cagrilintide 10mg

R1,600.00
In Stock 10mg
Save 14% + R160.00 delivery
Seranova logo
Seranova

Cagrilintide 10mg

R1,850.00
In Stock 10mg
+ R250.00 delivery

More ways to compare Cagrilintide

Different views of the same live SA pricing, tuned for how you like to shop.

Best Cagrilintide Prices Best prices ranked Cheapest Cagrilintide Prices Cheapest suppliers compared Where to Buy Cagrilintide Full buyer's guide Buy Cagrilintide Online SA Cheap Today's hottest deals Cagrilintide Price Comparison Live price dashboard Cagrilintide SA Supplier Verified SA supplier directory Cagrilintide For Sale Browse listings for sale

Compare another peptide

PeptideSupermarket® compares prices but doesn't sell products.

All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.

We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.

By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.

Cagrilintide Profile

Extensively Studied

Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes

Overview

Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination.

Mechanism of Action

Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.

Key Benefits

  • FDA development candidate with extensive Phase 3 data
  • Superior weight loss in combination with semaglutide (22.7%)
  • Once-weekly convenience
  • 2.2% HbA1c reduction with CagriSema

Quick Stats

Typical Dose
2.4mg weekly (after escalation)
Frequency
Once weekly, same day each week
Cycle Duration
Continuous long-term therapy
Storage
Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use within 30 days

Molecular Information

Molecular Weight
4,409.01 Da
Length
37 amino acids
Type
Amylin receptor agonist
Half-Life
~7 days (159-195 hours)

Amino Acid Sequence

37-amino acid peptide

Modifications

N-terminal lipidation with γ-glutamic acid spacer and C20 fatty diacid Engineered mutations reduce β-sheet formation and fibril propensity

Research Indications

The following information is derived from published scientific literature and is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. These peptides are not approved for human use and are sold exclusively for in-vitro laboratory research.

Obesity (Monotherapy)

Effective

Phase 3 trials demonstrate significant weight loss.

Obesity (CagriSema Combination)

Most Effective

22.7% weight loss with CagriSema combination, surpassing existing therapies.

Weight Loss in Diabetic Patients

Most Effective

15.7% weight loss in diabetic patients with concurrent glycemic improvements.

Glycemic Control

Most Effective

2.2% HbA1c reduction with CagriSema versus semaglutide alone.

Insulin Sensitivity

Effective

Amylin receptor activation enhances insulin sensitivity and glucose metabolism.

Satiety Enhancement

Effective

Dual pathway satiety via amylin and calcitonin receptor activation.

Dosing Protocols

injectable

Subcutaneous injection to abdomen, thigh, or upper arm. Pre-filled pen design when commercially available.

Goal Dose Frequency Route
Weight Loss (Monotherapy) 2.4mg Once weekly SubQ
Weight Loss (CagriSema) 2.4mg + semaglutide 2.4mg Once weekly SubQ
Type 2 Diabetes Management 2.4mg weekly Once weekly SubQ with metformin
Dose Escalation Protocol 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg Weekly increases over 16 weeks SubQ

Key Tips

  • Once-weekly convenience
  • Pre-filled pen design when approved
  • Dual receptor targeting
Materials Needed
Bacteriostatic water (standard BAC water acceptable for <30 days) Optional: 0.6% acetic acid to adjust pH to ~4.0 Insulin syringes Alcohol swabs
Steps
  1. 1 CRITICAL: Requires acidic pH (3.5-4.5) to prevent fibril formation
  2. 2 Reconstitute slowly down vial side; swirl gently (do not shake)
  3. 3 Verify pH 3.5-4.5 after reconstitution
  4. 4 Solution must be clear—discard if cloudy or particulate
  5. 5 Store refrigerated (2-8°C); inspect before each injection
  6. 6 Allow 15-30 minutes to reach room temperature before injection
  7. 7 Rotate injection sites weekly

Peptide Interactions

Semaglutide

Synergistic

CagriSema combination achieves enhanced weight loss through complementary GLP-1 and amylin pathways.

Tirzepatide

Compatible

No known direct interactions; different mechanisms allow concurrent use.

Retatrutide

Monitor

Compounded GI side effects create substantial risk without specialist supervision.

Metformin

Compatible

Well-tolerated in Phase 2/3 trials with no pharmacokinetic interactions.

SGLT2 Inhibitors

Compatible

Clinical trials demonstrated safe concurrent use with complementary mechanisms.

Pramlintide

Avoid

Both are amylin agonists; combination provides no additional benefit and increases GI risks.

Oral Contraceptives

Monitor

Delayed gastric emptying may affect absorption; space administration by 1 hour.

What to Expect

Week 1-2

Gastrointestinal adaptation; mild nausea possible during dose escalation

Week 4-8

Early weight loss (2-5%); noticeable appetite reduction

Week 12-26

Significant weight loss acceleration (10-15%); improved satiety signals

Week 26+

Peak efficacy (15-23% weight loss); sustained maintenance with continued therapy

Side Effects & Safety

Common Side Effects

  • Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
  • Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
  • Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial

Monitoring

  • No clinically significant QT prolongation observed
  • Monitor for fibril formation in reconstituted solution (must remain clear)

Stop Signs

  • Severe persistent nausea/vomiting preventing hydration
  • Pancreatitis signs (severe abdominal pain radiating to back)
  • Severe allergic reactions or anaphylaxis
  • Significant injection site reactions or abscess formation

Contraindications

  • Not recommended in pregnancy or breastfeeding
  • Not yet commercially available (FDA approval expected Q1 2026)

Quality Checklist

Good Signs

  • Pre-filled pen design when approved
  • Pharmaceutical grade purity >98%
  • Frozen storage stability at -20°C
  • Extended stability over 7-day dosing interval

Warning Signs

  • Standard bacteriostatic water acceptable short-term but may degrade at neutral pH; optimal stability requires pH ~4.0

Bad Signs

  • Fibril formation at improper pH—solution must remain clear
  • Aggregation or precipitation indicates degradation

Research & References

Key References

  1. 2025

    REDEFINE 1 Trial - Phase 3 Weight Loss

    3,417 adults with obesity; 22.7% weight loss with CagriSema vs 2.4% placebo. New England Journal of Medicine.

  2. 2025

    REDEFINE 2 Trial - Phase 3 Type 2 Diabetes

    1,206 adults; 15.7% weight loss; 73.5% achieved HbA1c ≤6.5%. New England Journal of Medicine.

  3. 2023

    Phase 2 Type 2 Diabetes Combination Study

    32 weeks; 15.6% weight loss; 2.2% HbA1c reduction with CagriSema. The Lancet.

Search PubMed for Cagrilintide

Research Library

Cagrilintide research & guides

Plain-English guides and study summaries from published literature.

View all 1
Cagrilintide Guide: Appetite Control, Satiety and Weight-Loss Research Guides 6 min

Cagrilintide Guide: Appetite Control, Satiety and Weight-Loss Research

Cagrilintide is a long-acting amylin analogue being studied for appetite regulation, weight management and type 2 diabetes, including in combination with semaglutide.

Read article

Get Peptide Price-drop Alerts

Be the first to know when prices drop on your favourite peptides

No spam. Unsubscribe anytime. We respect your privacy.